quinazolines has been researched along with Nervous System Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alpini, G; DeMorrow, S; Frampton, G; Galindo, C; McMillin, M; Standeford, H; Thompson, M; Whittington, E | 1 |
| Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P | 1 |
2 other study(ies) available for quinazolines and Nervous System Disorders
| Article | Year |
|---|---|
Neuronal CCL2 is upregulated during hepatic encephalopathy and contributes to microglia activation and neurological decline.
Topics: Animals; Azoxymethane; Benzamides; Body Temperature; Body Weight; Carcinogens; Chemokine CCL2; Disease Models, Animal; Enzyme Inhibitors; Glycine; Hepatic Encephalopathy; Liver; Male; Mice; Mice, Inbred C57BL; Microglia; Nervous System Diseases; Quinazolines; Signal Transduction; Time Factors; Up-Regulation | 2014 |
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Quinazolines; Salvage Therapy; Thiophenes; Treatment Outcome | 2001 |